Regulatory science strategy

The European Medicines Agency's (EMA) 'Regulatory Science to 2025' strategy is a plan for advancing EMA's engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. The strategy aims to build a more adaptive regulatory system that will encourage innovation in human and veterinary medicine. EMA consulted with stakeholders on the draft strategy via a public consultation and dedicated workshops.

Regulators need to have optimal tools to keep pace with scientific and technological advances and ensure the sound assessment of ground-breaking, more complex therapies.

‘Regulatory science’ refers to the range of scientific disciplines that are applied to the quality, safety and efficacy assessment of medicinal products and that inform regulatory decision-making throughout the lifecycle of a medicine. It encompasses basic and applied biomedical and social sciences and contributes to the development of regulatory standards and tools.

Regulatory Science Strategy to 2025

Regulatory Science Strategy 2025 coverUpdate: On 31 March 2020, EMA published its Regulatory Science Strategy to 2025 after it was endorsed by EMA's Management Board at its March 2020 meeting.

 

 

The five key goals of the strategy include:

  • catalysing the integration of science and technology in medicine development;
  • driving collaborative evidence generation to improve the scientific quality of evaluations;
  • advancing patient-centred access to medicines in partnership with healthcare systems (for human medicines only);
  • addressing emerging health threats;
  • enabling and leveraging research and innovation in regulatory science.­

The strategy seeks to offer informed guidance on modern medicines development, facilitate the optimisation of regulatory science and critically assess the benefits and risks of innovative therapies and diagnostics based on new technologies.

It identifies key areas where new or enhanced engagement of the European medicines regulatory network is essential and where advances in regulatory science are necessary. It also helps to shape the vision for the next EU Medicines Agencies Network Strategy (2020 - 2025).

Consultation process

Update: On 31 March 2020, EMA published a summary and corresponding analysis of the key points raised during the public consultation.

 

In preparation for the launch of its draft 'Regulatory science to 2025' strategy, EMA organised two workshops, where participants reflected on the scientific and technological advances in the pharmaceutical arena, and the future challenges that EMA’s scientific committees and working parties will face due to these developments. For more information, including supporting materials, see:

In December 2018, EMA started a six-month public consultation on its PDF icondraft 'Regulatory science to 2025' strategy to gather feedback from stakeholders. Around 150 individuals and organisations submitted comments.

EMA subsequently organised separate human and veterinary medicines workshops to consult stakeholders on the outcome of the analysis of the public consultation and identify concrete actions in order to implement the key goals and recommendations. 

The workshops brought together representatives from EMA's regulatory partners and stakeholders, including national competent authorities, patients’, healthcare professionals’ and veterinarians’ organisations, health technology assessment bodies, payer organisations and the pharmaceutical industry. For more information, see:

How useful was this page?

Add your rating
Average
8 ratings
1 rating
1 rating